Cargando…

Exploratory factor analysis determines latent factors in Guillain–Barré syndrome

Exploratory factor analysis (EFA) has been developed as a powerful statistical procedure in psychological research. EFA’s purpose is to identify the nature and number of latent constructs (= factors) underlying a set of observed variables. Since the research goal of EFA is to determine what causes t...

Descripción completa

Detalles Bibliográficos
Autores principales: Omura, Seiichi, Shimizu, Kazuaki, Kuwahara, Motoi, Morikawa-Urase, Miyuki, Kusunoki, Susumu, Tsunoda, Ikuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758666/
https://www.ncbi.nlm.nih.gov/pubmed/36528634
http://dx.doi.org/10.1038/s41598-022-26422-5
_version_ 1784852090048217088
author Omura, Seiichi
Shimizu, Kazuaki
Kuwahara, Motoi
Morikawa-Urase, Miyuki
Kusunoki, Susumu
Tsunoda, Ikuo
author_facet Omura, Seiichi
Shimizu, Kazuaki
Kuwahara, Motoi
Morikawa-Urase, Miyuki
Kusunoki, Susumu
Tsunoda, Ikuo
author_sort Omura, Seiichi
collection PubMed
description Exploratory factor analysis (EFA) has been developed as a powerful statistical procedure in psychological research. EFA’s purpose is to identify the nature and number of latent constructs (= factors) underlying a set of observed variables. Since the research goal of EFA is to determine what causes the observed responses, EFA is ideal for hypothesis-based studies, such as identifying the number and nature of latent factors (e.g., cause, risk factors, etc.). However, the application of EFA in the biomedical field has been limited. Guillain–Barré syndrome (GBS) is peripheral neuropathy, in which the presence of antibodies to glycolipids has been associated with clinical signs. Although the precise mechanism for the generation of anti-glycolipid antibodies is unclear, we hypothesized that latent factors, such as distinct autoantigens and microbes, could induce different sets of anti-glycolipid antibodies in subsets of GBS patients. Using 55 glycolipid antibody titers from 100 GBS and 30 control sera obtained by glycoarray, we conducted EFA and extracted four factors related to neuroantigens and one potentially suppressive factor, each of which was composed of the distinct set of anti-glycolipid antibodies. The four groups of anti-glycolipid antibodies categorized by unsupervised EFA were consistent with experimental and clinical findings reported previously. Therefore, we proved that unsupervised EFA could be applied to biomedical data to extract latent factors. Applying EFA for other biomedical big data may elucidate latent factors of other diseases with unknown causes or suppressing/exacerbating factors, including COVID-19.
format Online
Article
Text
id pubmed-9758666
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97586662022-12-19 Exploratory factor analysis determines latent factors in Guillain–Barré syndrome Omura, Seiichi Shimizu, Kazuaki Kuwahara, Motoi Morikawa-Urase, Miyuki Kusunoki, Susumu Tsunoda, Ikuo Sci Rep Article Exploratory factor analysis (EFA) has been developed as a powerful statistical procedure in psychological research. EFA’s purpose is to identify the nature and number of latent constructs (= factors) underlying a set of observed variables. Since the research goal of EFA is to determine what causes the observed responses, EFA is ideal for hypothesis-based studies, such as identifying the number and nature of latent factors (e.g., cause, risk factors, etc.). However, the application of EFA in the biomedical field has been limited. Guillain–Barré syndrome (GBS) is peripheral neuropathy, in which the presence of antibodies to glycolipids has been associated with clinical signs. Although the precise mechanism for the generation of anti-glycolipid antibodies is unclear, we hypothesized that latent factors, such as distinct autoantigens and microbes, could induce different sets of anti-glycolipid antibodies in subsets of GBS patients. Using 55 glycolipid antibody titers from 100 GBS and 30 control sera obtained by glycoarray, we conducted EFA and extracted four factors related to neuroantigens and one potentially suppressive factor, each of which was composed of the distinct set of anti-glycolipid antibodies. The four groups of anti-glycolipid antibodies categorized by unsupervised EFA were consistent with experimental and clinical findings reported previously. Therefore, we proved that unsupervised EFA could be applied to biomedical data to extract latent factors. Applying EFA for other biomedical big data may elucidate latent factors of other diseases with unknown causes or suppressing/exacerbating factors, including COVID-19. Nature Publishing Group UK 2022-12-17 /pmc/articles/PMC9758666/ /pubmed/36528634 http://dx.doi.org/10.1038/s41598-022-26422-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Omura, Seiichi
Shimizu, Kazuaki
Kuwahara, Motoi
Morikawa-Urase, Miyuki
Kusunoki, Susumu
Tsunoda, Ikuo
Exploratory factor analysis determines latent factors in Guillain–Barré syndrome
title Exploratory factor analysis determines latent factors in Guillain–Barré syndrome
title_full Exploratory factor analysis determines latent factors in Guillain–Barré syndrome
title_fullStr Exploratory factor analysis determines latent factors in Guillain–Barré syndrome
title_full_unstemmed Exploratory factor analysis determines latent factors in Guillain–Barré syndrome
title_short Exploratory factor analysis determines latent factors in Guillain–Barré syndrome
title_sort exploratory factor analysis determines latent factors in guillain–barré syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758666/
https://www.ncbi.nlm.nih.gov/pubmed/36528634
http://dx.doi.org/10.1038/s41598-022-26422-5
work_keys_str_mv AT omuraseiichi exploratoryfactoranalysisdetermineslatentfactorsinguillainbarresyndrome
AT shimizukazuaki exploratoryfactoranalysisdetermineslatentfactorsinguillainbarresyndrome
AT kuwaharamotoi exploratoryfactoranalysisdetermineslatentfactorsinguillainbarresyndrome
AT morikawaurasemiyuki exploratoryfactoranalysisdetermineslatentfactorsinguillainbarresyndrome
AT kusunokisusumu exploratoryfactoranalysisdetermineslatentfactorsinguillainbarresyndrome
AT tsunodaikuo exploratoryfactoranalysisdetermineslatentfactorsinguillainbarresyndrome